|
Match
|
Document |
Document Title |
|
|
US20120128771 |
TIMED, PULSATILE RELEASE SYSTEMS
A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is...
|
|
|
US20110002989 |
METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD
The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment,...
|
|
|
US20110123618 |
Controlled release formulation of lamotrigine
Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the...
|
|
|
US20110287100 |
Galenic Formulations of Organic Compounds
A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount...
|
|
|
US20100297224 |
NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
The present invention generally relates to pharmaceutical unit dosage forms of NSAIDs and H2-receptor antagonists, in which the H2-receptor antagonist is formulated so as to be released in a...
|
|
|
US20110081412 |
ORALLY DISINTEGRABLE TABLETS
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated ...
|
|
|
US20110300217 |
HYDROMORPHONE THERAPY
A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
|
|
|
US20110091548 |
USE OF A MATRIX FOR ORALLY ADMINISTERING SUSTAINED RELEASE MAGNESIUM, AND COMPOSITION CONTAINING SAID MATRIX
A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to...
|
|
|
US20110268795 |
Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions
The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release...
|
|
|
US20100015222 |
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage...
|
|
|
US20110052685 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN
Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon...
|
|
|
US20110142905 |
COATED TABLETS WITH REMAINING DEGRADATION SURFACE OVER THE TIME
The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet,...
|
|
|
US20100330172 |
CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION
A pharmaceutical formulation comprising desvenlafaxine having an MMD of between about 5 μm and about 100 μm, or a pharmaceutically acceptable salt thereof, and at least one matrix r...
|
|
|
US20110159088 |
ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS
The field of the present invention is that of oral pharmaceutical forms of at least one active principle AP whose solubility varies greatly as a function of the gastric pH, and also treatments and...
|
|
|
US20070281018 |
SUSTAINED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods...
|
|
|
US20110200671 |
METHOD OF TREATING A DISEASE CONDITION SUSCEPTIBLE TO BACLOFEN THERAPY
The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release...
|
|
|
US20110212174 |
CONTROLLED RELEASE ARGININE FORMULATIONS
A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic...
|
|
|
US20110059169 |
Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
|
|
|
US20060165790 |
Multiparticulates
Multipartulates of oxycodone can be made by extrusion of a blend which suitably contains (a) oxycodone, (b) water-insoluble ammonium methacrylate copolymer, (c) plasticiser, (d) lubricant and (e)...
|
|
|
US20110038930 |
HOT-MELT EXTRUDED PHARMACEUTICAL DOSAGE FORM
The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the...
|
|
|
US20060269601 |
Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support
This invention is directed to an oral modified release formulation of the phytoestrogen 8-prenylnaringenin and methods for the treatment of symptoms of estrogen deficiency.
|
|
|
US20100323007 |
A POLYAMIDE RATE-MODULATED MONOLITHIC DRUG DELIVERY SYSTEM
This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is...
|
|
|
US20110150994 |
Modified Release Formulation
The invention is directed to the use of an extended release tablet formulation for pramipexole.
|
|
|
US20060029668 |
Sustained release L-arginine formulations and methods of manufacture and use
The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in...
|
|
|
US20090214643 |
IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES
Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists...
|
|
|
US20110064803 |
NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2
The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an...
|
|
|
US20090011016 |
Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at...
|
|
|
US20050271723 |
Dosage forms for treatment of benign prostatic hyperplasia
A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidarrine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an...
|
|
|
US20100310653 |
USE OF AN EXTRACT MADE OF LEAVES OF GINKGO BILOBA
The present invention relates to the use of an extract made of leaves of Ginkgo biloba for the production of a preparation, or an extract made of leaves of Ginkgo biloba as an agent for the...
|
|
|
US20100221328 |
SUSTAINED-RELEASE FORMULATIONS
Described herein are extended-release or sustained-release formulations suitable for highly soluble pharmacologically active compounds, for example, amantadine. Dosage units for providing extended...
|
|
|
US20110142932 |
Pharmaceutical Tablets Comprising a Plurality of Segments
Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.
|
|
|
US20120087979 |
EXTENDED-RELEASE ORAL DOSAGE FORMS FOR POORLY SOLUBLE AMINE DRUGS
Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling...
|
|
|
US20100303907 |
STANDARDIZED PLANT EXTRACT, PROCESS FOR OBTAINING THE SAME AND USES THEREOF
The present invention refers to a process for obtaining a standardized extract having antinociceptive, anti-inflammatory and antipyretic properties, from at least one part of a plant of genus...
|
|
|
US20070178051 |
STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
The invention is directed sterile to compositions of glucocorticosteroids useful in the prophylaxis and chronic treatment of asthma and other allergic and inflammatory conditions in adults and...
|
|
|
US20110195122 |
Extended Release Formulation
The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.
|
|
|
US20060251720 |
Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
The present invention relates to a localized controlled absorption formulation of a statin in which rapid release of the active ingredient preferentially occurs in the lower gastrointestinal tract...
|
|
|
US20110038931 |
COMPOSITE PREPARATION
The present invention provides a combination preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active...
|
|
|
US20070122477 |
Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat...
|
|
|
US20100255093 |
SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG
Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
|
|
|
US20100015223 |
Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion
Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a...
|
|
|
US20100215738 |
PREBIOTIC FORMULATIONS AND METHODS OF USE
The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and...
|
|
|
US20110244034 |
SUSTAINED RELEASE DRUG DELIVERY SYSTEM
The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12...
|
|
|
US20090047345 |
Sustained-release tramadol formulations with 24-hour efficacy
A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect...
|
|
|
US20090092658 |
NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS
The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability,...
|
|
|
US20070042040 |
Methods and compositions using gonadotropin hormone releasing hormone
The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an...
|
|
|
US20070059365 |
Novel formulation of ropinirole
The present invention relates to novel formulations of ropinirole for oral administration and to their use in the treatment of diseases which can prevent or disturb sleep, particularly Restless...
|
|
|
US20100316709 |
ORALLY DISINTEGRATING SOLID PREPARATION
The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of...
|
|
|
US20110287095 |
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
|
|
|
US20110150989 |
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
|
|
|
US20110287099 |
Sustained-release formulations of topiramate
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
|